The BOSTON-1 and BOSTON-2 are Phase III studies designed to evaluate the safety and efficacy of investigational Liposomal Cyclosporine A (L-CsA-i) in patients with bronchiolitis obliterans syndrome (BOS) following a single or double lung transplant.
About Clinical Trials
The BOSTON-1 and BOSTON-2 Phase III clinical research trials are investigating the safety and the effectiveness of Liposomal Cyclosporine A for Inhalation (L-CsA-i), administered via the investigational eFlow® Technology nebulizer system, as a treatment for Bronchiolitis Obliterans Syndrome (BOS), when added to the standard of care regimen after lung transplantation.
You are now leaving our website. This link is being provided as a convenience and for informational purposes only; we bear no responsibility for the accuracy and content of the external site or for that of subsequent links.